Atrys will make its debut tomorrow on the MAB, after receiving the approval of the MAB incorporations committee. The company, which is the 35th company to be listed in the growth company category, is engaged in the provision of diagnostic services and medical treatments and the development of new therapeutic modalities and diagnostic tools.
About Atrys
Atrys was founded in 2007 by a group of physicians and cancer experts led by Dr. Carlos Cordón-Cardó, director of the Department of Pathology at Mount Sinai Hospital (New York, USA). Its aim was to provide a new model in the clinical management of cancer by combining innovative precision diagnostic techniques in pathology and molecular anatomy with new radiotherapy treatments.
It currently operates in Opera in America and Europe, with clients in 7 countries, the United States, Switzerland, the United Kingdom, Germany, Denmark, Portugal and Spain. It closed 2015 with a turnover of €2.8m and 50 employees.
In 2015 it acquired eDiagnostic, a telemedicine company offering services in the specialties of Radiology, Cardiology, Ophthalmology and Dermatology.
Preparing for Mab listing: Capital increase
In preparation for its Mab listing, Atrys has carried out a €4.5m capital increase to raise equity to finance the opening of new radiotherapy centres and new diagnostic services, as well as the company's international expansion.
The shareholders of Atrys are InvereadyThe venture capital investment group (37.6 %); the scientific and management team (37 %) and the rest of the shareholding Family Offices.
The shareholders of Atrys are willing to remain in the capital and have made a 12-month commitment to stay in the company.
Details of your exit to the Mab
Tomorrow this company will debut on the Mab, initial capitalisation at €16.5M. According to a statement from BME, the reference price will be €1.48 per share.
The company will be listed on the MAB through the price fixing system by means of the confluence of supply and demand in two daily auction periods or "fixings" (12.00 p.m. and 4.00 p.m.).
Norgestión is the company's registered advisor and Banco Sabadell acts as liquidity provider.
Other posts that may interest you
Clerhp structures exits the mab up 10.24%
TECNOQUARK goes public on the MAB to finance growth
If you are thinking of going public on the MAB, contact us. Abra-Invest has an expert team that will advise you to make the process a success. Call us at + 34 946424142 or fill in the contact form.
